NBTXR3
Funding or dealCompany-reported
- What happened
Nanobiotix licensed NBTXR3 to Janssen, a Johnson & Johnson company, for development and sale worldwide.
- Why it matters
Nanobiotix says the particles magnify the X-ray dose inside the tumor while the dose passing through healthy tissue stays the same.
Nanobiotix via BioSpace, 4 Apr 2019- How far from your life
Approved or on sale
Hafnium oxide nanoparticles for radiotherapy (NBTXR3) is on step 4 of 5. You can get it now, though it may not be common yet.
- Source
“In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3)”Nanobiotix, 24 Sept 2026
Company-reported: the only source so far is the company itself. It still counts on the ladder, and we show the flag until an independent source backs it.
The bigger picture
More on NBTXR3
On step 4 of 5: Approved or on sale. Everything we track on it
- Human trialCompany-reported
Nanobiotix reported that the FDA had cleared changes to the Johnson & Johnson-led phase 3 trial in head and neck cancer, NANORAY-312, so that its final analysis can come sooner.
Nanobiotix, 24 Sept 2026 - ApprovalCompany-reported
Nanobiotix said its product, sold under the name Hensify, won a CE mark in Europe for locally advanced soft tissue sarcoma.
Nanobiotix via BioSpace, 4 Apr 2019